Syros Pharmaceuticals, Inc. (SYRS)
OTCMKTS · Delayed Price · Currency is USD
0.0001
-0.0003 (-75.00%)
At close: Jun 18, 2026
Syros Pharmaceuticals Revenue
Syros Pharmaceuticals had revenue of $386.00K in the twelve months ending September 30, 2024, down -95.61% year-over-year. In the year 2023, Syros Pharmaceuticals had annual revenue of $9.94M, down -33.23%.
Revenue (ttm)
386.00K
Revenue Growth
-95.61%
P/S Ratio
0.01
Revenue / Employee
5.68K
Employees
68
Market Cap
2.68K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9.94M | -4.94M | -33.23% |
| Dec 31, 2022 | 14.88M | -8.61M | -36.65% |
| Dec 31, 2021 | 23.49M | 8.40M | 55.62% |
| Dec 31, 2020 | 15.09M | 13.11M | 661.50% |
| Dec 31, 2019 | 1.98M | -68.00K | -3.32% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ONE Bio | 53.91M |
| Synovics Pharmaceuticals | 19.09M |
| EV Biologics | 9.47M |
| Alzex Neuropharma | 4.73M |
| Kaleido Biosciences | 1.10M |
| Comera Life Sciences Holdings | 1.00M |
Syros Pharmaceuticals News
- 1 year ago - Syros Pharmaceuticals sells Tamibarotene assets to Rege Nephro - TheFly
- 1 year ago - Syros Pharmaceuticals trading resumes - TheFly
- 1 year ago - Syros Pharmaceuticals voluntarily delists from Nasdaq, deregisters common stock - TheFly
- 1 year ago - Syros Pharmaceuticals trading halted, news pending - TheFly
- 1 year ago - Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration - Business Wire
- 1 year ago - Syros Pharmaceuticals downgraded to Hold from Buy at TD Cowen - TheFly
- 1 year ago - Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 1 year ago - Syros downgraded to Market Perform from Outperform at JMP Securities - TheFly